Item 1. Financial Statements
Item 1 – Financial Statements
TEMPEST THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
June 30, 2025
(Unaudited)
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$
14,280
$
30,268
Prepaid expenses and other current assets
823
1,206
Total current assets
15,103
31,474
Property and equipment — net
748
886
Operating lease right-of-use assets
8,104
8,643
Other noncurrent assets
529
485
Total assets
$
24,484
$
41,488
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
4,716
$
2,450
Accrued expenses
1,221
2,726
Current loan payable (net of discount and issuance costs of nil and $ 74 , respectively)
—
6,354
Current operating lease liabilities
1,103
869
Accrued compensation
101
1,762
Interest payable
—
59
Total current liabilities
7,141
14,220
Operating lease liabilities, less current portion
7,560
8,142
Total liabilities
14,701
22,362
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $ 0.001 par value; 100,000,000 shares authorized; 4,437,855 and 3,382,432 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively (1)
4
3
Additional paid-in capital (1)
235,615
226,229
Accumulated deficit
( 225,836
)
( 207,106
)
Total stockholders’ equity
9,783
19,126
Total liabilities and stockholders’ equity
$
24,484
$
41,488
(1) Results, including shares issued and outstanding have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.
See accompanying Notes to the Condensed Consolidated Financial Statements
5
Table of Contents
TEMPEST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Operating expenses:
Research and development
$
3,871
$
5,837
$
11,498
$
10,177
General and administrative
4,095
3,745
7,404
7,379
Loss from operations
( 7,966
)
( 9,582
)
( 18,902
)
( 17,556
)
Other income (expense), net:
Interest expense
( 46
)
( 372
)
( 207
)
( 740
)
Interest income and other income (expense), net
142
384
379
822
Total other income (expense), net
96
12
172
82
Provision for income taxes
—
—
—
—
Net loss
$
( 7,870
)
$
( 9,570
)
$
( 18,730
)
$
( 17,474
)
Net loss per share of common stock, RSUs and pre-funded warrants, basic and diluted (1)
$
( 2.07
)
$
( 5.52
)
$
( 5.17
)
$
( 10.15
)
Weighted-average shares of common stock, RSUs and pre-funded warrants outstanding, basic and diluted (1)
3,802,956
1,734,335
3,621,329
1,722,327
(1) Results, including shares of common stock, have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.
See accompanying Notes to the Condensed Consolidated Financial Statements
6
Table of Contents
TEMPEST THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
(in thousands, except share amounts)
Six Months Ended June 30, 2025
Common Stock
Additional
Paid-In
Accumulated
Total
Stockholders'
Shares (1)
Amount (1)
Capital (1)
Deficit
Equity
BALANCE — December 31, 2024
3,382,432
$
3
$
226,229
$
( 207,106
)
$
19,126
Issuance of common stock in connection with at-the-market offering (net of issuance costs of $ 84 )
133,521
1
1,443
—
1,444
Stock-based compensation
—
—
1,389
—
1,389
Issuance of common stock under equity plan awards
3,649
—
34
—
34
Net loss
—
—
—
( 10,860
)
( 10,860
)
BALANCE — March 31, 2025
3,519,602
$
4
$
229,095
$
( 217,966
)
$
11,133
Issuance of common stock for cash (net of issuance costs of $ 319 )
584,253
—
3,570
—
3,570
Stock-based compensation
—
—
1,092
—
1,092
Issuance of pre-funded warrants, (net of issuance costs of $ 230 )
334,000
—
1,858
—
1,858
Net loss
—
—
—
( 7,870
)
( 7,870
)
BALANCE — June 30, 2025
4,437,855
$
4
$
235,615
$
( 225,836
)
$
9,783
Six Months Ended June 30, 2024
Common Stock
Additional
Paid-In
Accumulated
Total
Stockholders'
Shares (1)
Amount (1)
Capital (1)
Deficit
Equity
BALANCE — December 31, 2023
1,695,788
$
2
$
192,029
$
( 165,263
)
$
26,768
Issuance of common stock in connection with at-the-market offering (net of issuance costs of $ 8 )
4,329
—
253
—
253
Stock-based compensation
—
—
1,318
—
1,318
Issuance of common stock under equity plan awards
8,901
—
197
—
197
Net loss
—
—
—
( 7,904
)
( 7,904
)
BALANCE — March 31, 2024
1,709,018
$
2
$
193,797
$
( 173,167
)
$
20,632
Issuance of common stock in connection with at-the-market offering (net of issuance costs of $ 261 )
164,118
—
4,557
—
4,557
Stock-based compensation
—
—
1,320
—
1,320
Issuance of common stock under equity plan awards
9,615
—
—
—
—
Net loss
—
—
—
( 9,570
)
( 9,570
)
BALANCE — June 30, 2024
1,882,751
$
2
$
199,674
$
( 182,737
)
$
16,939
(1) Shares issued and outstanding have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.
See accompanying Notes to the Condensed Consolidated Financial Statements.
7
Table of Contents
TEMPEST THERAPEUTICS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
For the Six Months
Ended June 30,
2025
2024
Operating activities:
Net loss
$
( 18,730
)
$
( 17,474
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
135
243
Stock-based compensation expense
2,481
2,638
Non-cash lease expense
539
793
Non-cash interest and other expense, net
76
104
Changes in operating assets and liabilities:
Prepaid expenses and other assets
339
709
Accounts payable
2,266
512
Accrued expenses and other liabilities
( 3,166
)
296
Interest payable
( 59
)
( 7
)
Operating lease liabilities
( 348
)
( 510
)
Cash used in operating activities
( 16,467
)
( 12,696
)
Investing activities:
Purchase of property and equipment
—
( 417
)
Cash used in investing activities
—
( 417
)
Financing activities:
Proceeds from the issuance of common stock, net of issuance costs
5,013
4,810
Proceeds from the issuance of pre-funded warrants, net of issuance costs
1,858
—
Repayment of loan
( 6,426
)
—
Proceeds from the issuance of common stock under equity plan awards
34
197
Cash provided by financing activities
479
5,007
Net decrease in cash, cash equivalents and restricted cash
( 15,988
)
( 8,106
)
Cash, cash equivalents and restricted cash at beginning of period
30,711
39,673
Cash, cash equivalents and restricted cash at end of period
$
14,723
$
31,567
Supplemental disclosure of cash flow information:
Cash paid for interest
$
192
$
651
Cash paid for business taxes
$
22
$
6
See accompanying Notes to the Condensed Consolidated Financial Statements
8
Table of Contents
TEMPEST THERAPEUTICS, INC.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(Amounts are in thousands, except share and per share data)
1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS
Description of Business
Tempest Therapeutics, Inc. (“Tempest” or the “Company”) is a clinical-stage biotechnology company moving into late-stage development with a diverse portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class treatments for a wide range of cancers. Tempest’s novel programs range from early research to the lead program, amezalpat (previously known as TPST-1120), that is poised to begin a pivotal study in first-line liver cancer. Tempest is also developing other potential product candidates in its Discovery Research group. The Company is headquartered in Brisbane, California.
Reverse Stock Split
On December 3, 2024, the Company held a special meeting of stockholders at which its stockholders approved a proposal to effect an amendment to the Company’s Restated Certificate of Incorporation to implement a reverse stock split. On April 4, 2025, the Company’s board of directors approved the filing of a certificate of amendment to the Company’s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect the one-for-thirteen (1:13) reverse stock split of its outstanding common stock (the "Reverse Stock Split").
On April 8, 2025, the Company effected the Reverse Stock Split. Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company’s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company’s equity incentive plans have been reduced proportionately. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.
No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder’s percentage ownership of the Company’s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share).
Liquidity and Going Concern
The Company has incurred operating losses since inception. As of June 30, 2025, the Company had $ 14.3 million of cash and cash equivalents. While the Company has begun to implement cost reductions in 2025, the Company has finite cash resources available to fund its operations. In April 2025 , the Company announced plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The Company has retained MTS Health Partners, L.P., an internationally recognized financial advisor with substantial experience in the biotechnology industry, to support it with the strategic evaluation process. If a strategic alternative is not available, the Company will be required to take additional actions to fund the Company’s operations, or it may be forced to wind down its operations. As part of the cost reductions, the Company reduced its workforce by 21 of 26 full-time employees, which became effective April 30, 2025 . Further, in support of such efforts, on June 5, 2025, each of Stephen Brady, the Company’s Chief Executive Officer and President, Samuel Whiting, the Company’s Executive Vice President and Chief Medical Officer, and Nicholas Maestas, the Company’s Chief Financial Officer and Head of Corporate Strategy, transitioned to consulting arrangements with the Company, pursuant to which they will continue to serve the Company in their respective executive roles. The Company incurred $ 3.2 million of one-time cash severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based compensation), with the majority of such costs incurred in the second quarter of 2025.
9
Table of Contents
The Company expects that its existing cash and cash equivalents will fund the Company’s projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these condensed financial statements. The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.
ATM Program
On July 23, 2021, the Company entered into a sales agreement with Jefferies LLC (“Jefferies”), pursuant to which the Company may sell, from time to time at its sole discretion through Jefferies, as its sales agent, shares of its common stock having, up to an aggregate sales price of $ 100.0 million of its common stock through Jefferies (the “Prior ATM Program”). As of June 20, 2024, the Company had sold an aggregate 9,017,110 shares of its common stock for gross proceeds of $ 42.7 million ($ 41.5 million net of commissions and estimated expenses) under the Prior ATM Program. On June 20, 2024, the Company and Jefferies terminated the Prior ATM Program and entered a new Open Market Sale Agreement (the “Sales Agreement”) to sell shares of common stock from time to time through Jefferies acting as sales agent (the “ATM Program”). The Company will pay Jefferies a commission up to 3.0 % of the gross sales proceeds of any shares of its common stock sold through Jefferies under the ATM Program and also has provided Jefferies with indemnification and contribution rights. Pursuant to the prospectus supplement dated June 20, 2024 filed by the Company with the U.S. Securities and Exchange Commission (“SEC”), the Company was able to offer and sell up to $ 205,000,000 of its shares of common stock pursuant to the Sales Agreement. On June 11, 2025, in connection with the RDO (as defined below), the Company delivered written notice to Jefferies that it was suspending and terminating the prospectus supplement, dated February 6, 2025, related to the ATM Program (the “ATM Prospectus”). The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.
As of the six months ended June 30, 2025, the Company has sold an aggregate of 312,830 shares of its common stock for proceeds of $ 2.8 million, pursuant to the ATM Program. As of June 30, 2025, $ 11.6 million remained available for sale under the ATM Program.
Under current SEC regulations, if at any time the Company's public float is less than $ 75.0 million, and for so long as the Company’s public float remains less than $ 75.0 million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. On February 6, 2025, the Company filed a prospectus supplement with the SEC limiting the availability under the ATM Program to $ 14.5 million.
Registered Direct Offering
On June 11, 2025, the Company sold an aggregate of 405,000 shares of the Company’s common stock and pre-funded warrants to purchase 334,000 shares of its common stock in a registered direct offering (“RDO”). The offering price was $ 6.25 per share of common stock and $ 6.249 per pre-funded warrant, which is the price of each share of common stock sold in the RDO, minus the $ 0.001 exercise price per pre-funded warrant. The net proceeds from the RDO were approximately $ 4.1 million, after deducting placement agent fees and estimated offering expenses payable by the Company. As of June 30, 2025, all pre-funded warrants had been exercised.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Significant Accounting Policies —The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange
10
Table of Contents
Commission (“SEC”) on March 27, 2025. There have been no material changes to the significant accounting policies during the six months ended June 30, 2025.
Basis of Presentation —The unaudited interim Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been omitted. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 .
The Company has prepared the accompanying Condensed Consolidated Financial Statements on the same basis as the audited financial statements, and the unaudited interim financial statements include, in the Company’s opinion, all adjustments, consisting only of normal recurring adjustments that the Company considers necessary for a fair presentation of its financial position and results of operations for these periods.
All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.
Use of Estimates —The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.
3 . FAIR VALUE MEASUREMENTS
The following tables present the Company’s fair value hierarchy for assets measured at fair value on a recurring basis:
As of June 30, 2025
Level 1
Level 2
Level 3
Total
Cash and cash equivalents
$
14,280
$
—
$
—
$
14,280
Total
$
14,280
$
—
$
—
$
14,280
As of December 31, 2024
Level 1
Level 2
Level 3
Total
Cash and cash equivalents
$
30,268
$
—
$
—
$
30,268
Total
$
30,268
$
—
$
—
$
30,268
4. BALANCE SHEET COMPONENTS
Prepaid expenses and other current assets consist of the following:
June 30,
2025
December 31,
2024
Prepaid expenses
$
231
$
642
Prepaid research and development costs
110
29
Other current assets
482
535
Total
$
823
$
1,206
11
Table of Contents
Property and equipment, net, consists of the following:
June 30,
2025
December 31,
2024
Computer equipment and software
$
192
$
192
Furniture and fixtures
328
328
Lab equipment
1,485
1,485
Leasehold improvements
198
201
Property and equipment
2,203
2,206
Less accumulated depreciation
( 1,455
)
( 1,320
)
Property and equipment—net
$
748
$
886
Depreciation expense for the three and six months ended June 30, 2025 was $ 67 and $ 135 , respectively. Depreciation expense for the three and six months ended June 30, 2024 was $ 155 and $ 243 , respectively.
Accrued liabilities consist of the following:
June 30,
2025
December 31,
2024
Accrued other liabilities
$
990
$
1,335
Accrued clinical trial liability
231
1,391
Total
$
1,221
$
2,726
5 . COMMITMENTS AND CONTINGENCIES
Facilities Lease Agreements
In January 2022, the Company entered into a new 8-year office lease agreement for a 20,116 square feet facility in Brisbane, California (“Brisbane Lease”). The lease commenced in December 2022 .
As of June 30, 2025 and December 31, 2024 , the balance of the operating lease right of use assets were $ 8,104 and $ 8,643 , respectively, and the related operating lease liabilities were $ 8,663 and $ 9,011 , respectively, as shown in the accompanying consolidated balance sheets.
Rent expense was $ 486 and $ 973 for the three and six months ended June 30, 2025 , respectively. Rent expense was $ 587 and $ 1,272 for the three and six months ended June 30, 2024, respectively.
As of June 30, 2025, future minimum lease payments under the Company's operating lease liabilities were as follows:
Year Ending
Total Commitment
2025 (excluding six months ended June 30, 2025)
$
931
2026
1,926
2027
1,994
2028 and beyond
6,410
Total minimum lease payments
11,261
Less: imputed interest
( 2,598
)
Present value of operating lease obligations
8,663
Less: current portion
( 1,103
)
Noncurrent operating lease obligations
$
7,560
12
Table of Contents
Related to this Brisbane Lease agreement, the Company entered into a letter of credit with a bank to deposit $ 388 in a separate account that is classified as restricted cash to serve as security rent deposit. This amount is included in other noncurrent assets in the accompanying consolidated balance sheets as of June 30, 2025 .
6 . LOAN PAYABLE
On January 15, 2021, the Company entered into a loan agreement with Oxford Finance LLC (the “Lender”) to borrow a term loan amount of $ 35,000 to be funded in three tranches (as amended, the “Loan Agreement”). Tranche A of $ 15,000 was wired to the Company on January 15, 2021. Tranche B of $ 10,000 expired on March 31, 2022 . Tranche C of $ 10,000 was available at the Lender’s option.
On December 23, 2022, the Company entered into a First Amendment to the Loan Agreement. The amendment modified the Loan Agreement as follows: (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Millendo”), were joined as co-borrowers under the Loan Agreement; (ii) the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances) ; and (iii) a security interest in all of the assets of the Company, TempestTx and Millendo, including any intellectual property, was granted to the Lender. In addition, the Lender permitted a one-time prepayment in the amount of $ 5.0 million, which the Company paid on December 23, 2022.
Following the amendment to the Loan Agreement, the term loan had a maturity date of August 1, 2025 and an annual floating interest rate of 7.15 %, which is an Index Rate plus 7.10 %. Index Rate is the greater of (i) 1-Month CME Term SOFR or (ii) 0.05 %. In the fourth quarter of 2023, the Company achieved the circumstances necessary to extend the interest-only repayment period through June 30, 2024. Monthly principal payments of $ 733 were required to begin on July 1, 2024. Related to this borrowing, the Company recorded loan discounts totaling $ 898 and paid $ 95 of debt issuance costs. These amounts would be amortized as additional interest expense over the life of the loan.
On April 8, 2025, using cash on hand, the Company made a repayment of $ 3.5 million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date, under the Loan Agreement with the Lender. The payoff amount paid by the Company in connection with the termination of the Loan Agreement was pursuant to a payoff letter with the Lender and included payment of $ 0.6 million as an exit fee. Upon making the repayment, the Loan Agreement was terminated in accordance with its terms and all liens and security interests granted thereunder to secure the obligations were released.
For the three and six months ended June 30, 2025 , total interest expense was $ 46 and $ 207 , respectively. For the three and six months ended June 30, 2024 , total interest expense was $ 372 and $ 740 , respectively.
7 . STOCKHOLDERS' EQUITY
Authorized Stock
The Company is authorized to issue 100,000,000 shares of common stock, par value of $ 0.001 per share, and 5,000,000 shares of preferred stock, 100,000 of which have been designated as Series A Participating Preferred Stock (the “Series A Preferred Stock”), par value of $ 0.001 per share pursuant to the Company’s adoption the Rights Plan (as defined below). No shares of the Company’s Series A Participating Preferred Stock were outstanding as of June 30, 2025 and 2024. Stockholders are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holders of each share of common stock are entitled to one vote and the holders of each share of Series A Preferred Stock, if issued, are entitled to 1,000 votes. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders.
13
Table of Contents
Rights Plan
On October 10, 2023, the Company’s Board of Directors adopted a limited duration stockholder rights plan (the “Rights Plan”), effective immediately, and declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock. The dividend was effective as of October 23, 2023 (the “Record Date”) with respect to stockholders of record on that date. The Rights will also attach to new common stock issued after the Record Date. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of the Series A Preferred Stock at a price of $ 25.00 per one one-thousandth of a preferred share, subject to adjustment. The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the “Rights Agreement"), between the Company and Computershare Trust Company, NA.
On October 9, 2024, the Company entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement. The Amendment extends the Final Expiration Date of the Rights Agreement until immediately following the Company’s 2025 Annual Meeting of Stockholders or, if the Company’s stockholders approve the Rights Plan at or prior to such meeting, to October 10, 2026, unless the Rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Agreement.
On December 5, 2024, the Company entered into Amendment No. 2 (the “Second Amendment”) to the Rights Agreement. The Second Amendment makes certain technical amendments to the rights and obligations of the Company’s Board of Directors to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.
8 . STOCK-BASED COMPENSATION
Equity Plans
In 2011, Private Tempest adopted the 2011 Equity Incentive Plan (the “2011 Plan), and in 2017, Private Tempest adopted the 2017 Equity Incentive Plan (the “2017 Plan”), and together with the 2011 Plan, the “Tempest Prior Plans.” The Tempest Prior Plans have been terminated and no additional grants may be made under either plan. All stock awards granted under the Tempest Prior Plans will remain subject to the terms of the applicable prior plan. As a result of the merger with Millendo, the Tempest Prior Plans were assumed by the Company.
On April 29, 2019, the Board of Millendo adopted the 2019 Equity Incentive Plan (the “2019 Plan”), subject to approval by the Company’s stockholders, and became effective with such stockholder approval on June 11, 2019. On June 17, 2022, the Company’s stockholders approved the Amended and Restated 2019 Equity Incentive Plan (the “A&R 2019 Plan”), which amended and restated the 2019 Plan and was the successor to, and replacement of, the 2019 Plan.
The Board of Tempest adopted the Amended and Restated 2023 Equity Incentive Plan (the “2023 Plan”) on April 30, 2023, subject to approval by the Company’s stockholders. On June 15, 2023, the Company’s stockholders approved the 2023 Plan, which amended and restated the A&R 2019 Plan and will be a successor to, and replacement of, the A&R 2019 Plan. The number of shares of the Company's common stock reserved for issuance under the 2023 Plan will automatically increase on January 1st of each year, for a period of 10 years, from January 1, 2024 continuing through January 1, 2033, by 4 % of the total number of shares of the Company's common stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares as may be determined by the Board of Directors. Accordingly, on January 1, 2025, the common stock reserved for issuance was increased by 135,297 shares. As of June 30, 2025, there were 47,745 shares available for future grant under the 2023 Plan.
The 2023 Plan allows the Company to grant stock awards to employees, directors and consultants of the Company, including incentive stock options (“ISOs”), non-qualified stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards.
14
Table of Contents
The Board of Tempest adopted the 2023 Inducement Plan (“2023 Inducement Plan”) on June 21, 2023, pursuant to which the Company reserved 88,461 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company’s Board of Directors without stockholder approval in accordance with such rule. As of June 30, 2025, there were 67,615 shares available for future grant under the 2023 Inducement Plan.
The Company measures employee and non-employee stock-based awards at grant date fair value and records compensation expense on a straight-line basis over the vesting period of the award.
Employee Stock Ownership Plan
The Millendo Board adopted the 2019 Employee Stock Purchase Plan on April 29, 2019, which became effective upon stockholder approval on June 11, 2019. On June 17, 2022, the Company’s stockholders approved the Amended and Restated 2019 Employee Stock Purchase Plan (the “2019 ESPP”). The 2019 ESPP enables employees to purchase shares of the Company's common stock through offerings of rights to purchase the Company's common stock to all eligible employees.
The 2019 ESPP provides that the number of shares of common stock reserved for issuance under the 2019 ESPP will automatically increase on January 1, 2023 and continuing through (and including) January 1, 2029, by the lesser of 1.5 % of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year, (ii) 38,461 shares of Common Stock, or (iii) such lesser number of shares of Common Stock as determined by the Board of Directors (which may be zero). On January 1, 2025, the common stock reserved for issuance was increased by 38,461 shares.
As of June 30, 2025 , 70,914 shares of common stock remained available for future issuance under the 2019 ESPP. During the three and six months ended June 30, 2025 , 3,649 shares of common stock were issued under the 2019 ESPP.
Stock Options
Options to purchase the Company’s common stock may be granted at a price not less than the fair market value in the case of both NSOs and ISOs, except for an options holder who owns more than 10% of the voting power of all classes of stock of the Company, in which case the exercise price shall be no less than 110 % of the fair market value per share on the grant date. Stock options granted under the Plans generally vest over four years and expire no later than ten ( 10 ) years from the date of grant. Vested options can be exercised at any time.
The following shows the stock option activities for the six months ended June 30, 2025 and 2024:
Total
Options
Outstanding
Weighted-Average
Exercise
Price
Balance—December 31, 2024
320,013
$
86.06
Granted
130,091
11.20
Exercised
—
—
Cancelled and forfeited
—
—
Balance—June 30, 2025
450,104
64.44
Balance—December 31, 2023
273,393
$
94.64
Granted
57,551
57.85
Exercised
( 6,284
)
24.83
Cancelled and forfeited
( 16,028
)
106.99
Balance—June 30, 2024
308,632
88.53
15
Table of Contents
The following table summarizes information about stock options outstanding at June 30, 2025:
Shares
Weighted
Average
Remaining
Contractual
Life (In Years)
Weighted
Average
Exercise Price
Aggregate
Intrinsic Value
Options outstanding
450,104
8.21
$
64.44
$
—
Vested and expected to vest
450,104
8.21
$
64.44
$
—
Exercisable
439,914
8.20
$
64.50
$
—
During the six months ended June 30, 2025 and 2024 , the Company granted employees and non-employees stock options to purchase 130,091 and 57,551 shares of common stock, respectively, with a weighted-average grant date fair value of $ 11.20 and $ 57.85 per share, respectively. As of June 30, 2025 and 2024 , total unrecognized compensation costs related to unvested employee stock options were $ 512 and $ 14,772 , respectively. These costs are expected to be recognized over a weighted-average period of approximately 2.0 years and 3.1 years, respectively.
The Company estimated the fair value of stock options using the Black-Scholes option pricing valuation model. The fair value of employee and non-employee stock options is being amortized on the straight-line basis over the requisite service period of the awards. The fair value of employee and non-employee stock options was estimated using the following assumptions for the six months ended June 30, 2025 and 2024:
2025
2024
Expected term (in years)
6.0
5.5 - 6.1
Expected volatility
115 % - 116 %
109 % - 113 %
Risk-free interest rate
4.4
%
3.8 % - 4.7 %
Dividends
—
%
—
%
Expected Term —The expected term of options granted represents the period of time that the options are expected to be outstanding. Due to the lack of historical exercise history, the expected term of the Company’s employee stock options has been determined utilizing the simplified method for awards that qualify as plain-vanilla options.
Expected Volatility —The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company did not have any trading history for the Company’s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company’s common stock becomes available.
Risk-Free Interest Rate —The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options.
Dividends —The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used.
16
Table of Contents
Stock-Based Compensation Expense
The following table summarizes the components of stock-based compensation expense recognized in the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2025:
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Research and development
$
380
$
559
$
970
$
1,105
General and administrative
712
761
1,511
1,533
Total
$
1,092
$
1,320
$
2,481
$
2,638
9 . RETIREMENT PLAN
The Company participates in a qualified 401(k) Plan sponsored by its professional service organization. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. During the three and six months ended June 30, 2025 , the Company contributed $ 35 and $ 115 to the 401(k) Plan, respectively. During the three and six months ended June 30, 2024 , the Company contributed $ 43 and $ 94 to the 401(k) Plan, respectively.
10. NET LOSS PER SHARE
The following table sets forth the computation of the Company’s basis in diluted net loss per share for the three and six months ended June 30, 2025 and 2024 (in thousands, except share and per share amounts):
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Numerator:
Net loss
$
( 7,870
)
$
( 9,570
)
$
( 18,730
)
$
( 17,474
)
Denominator:
Weighted-average common shares outstanding
3,802,956
1,734,335
3,621,329
1,722,327
Weighted-average shares used in computing basic and diluted net loss per share
3,802,956
1,734,335
3,621,329
1,722,327
Net loss per share attributable to common stockholders—basic and diluted
$
( 2.07
)
$
( 5.52
)
$
( 5.17
)
$
( 10.15
)
As of June 30, 2025 and 2024 , the Company’s potentially dilutive securities included unvested stock warrants and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. The issuance of pre-funded warrants and vested RSUs have been included in the computation of basic and diluted net loss per share attributable to common stockholders. Based on the amounts outstanding as of June 30, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:
As of June 30,
2025
2024
Options to purchase common stock
450,104
308,631
Common stock warrants
464
464
Total
450,568
309,095
17
Table of Contents
11. SEGMENT REPORTING
The Company operates and manages its business as one reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer . The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
As the Company has not generated revenue, the CODM assesses Company performance through the achievement of research goals towards advancing the Company’s product candidates through stages of development. As such, the CODM is regularly provided with budgeted and forecasted expense information as well as the Company’s Consolidated Financial Statements which is used to determine the Company’s liquidity needs and pipeline resource allocation.
The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company’s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources. The consolidated net loss and significant segment expenses reviewed by the CODM are reported on the Company’s Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets. The CODM monitors the Company's cash and cash equivalents as reported on the Consolidated Balance Sheets.
All financial information required for segment reporting that is provided to the chief operating decision maker is contained within the financial statements and notes to financial statements.
12. SUBSEQUENT EVENTS
U.S. Tax Regulation Update
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted into law in the United States. OBBBA includes significant changes, such as the permanent extension of certain provisions that were originally enacted in the 2017 Tax Cuts and Jobs Act and were set to expire on December 31, 2025, modifications to certain international tax provisions and the restoration of tax treatment for certain business expense provisions. The new legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We are currently assessing the impact on our condensed consolidated financial statements, as well as our annual estimated effective tax rate.
Compensation Arrangements
On August 11, 2025, the Company entered into success bonus agreements with certain individuals, including Stephen Brady, the Company’s Chief Executive Officer and President, Samuel Whiting, the Company’s Executive Vice President and Chief Medical Officer, Nicholas Maestas, the Company’s Chief Financial Officer and Head of Corporate Strategy, and Justin Trojanowski, the Company’s Corporate Controller, Treasurer and principal accounting officer, for total aggregate success bonuses of $ 725,000 . Pursuant to the agreements, the individuals will be eligible to receive a success bonus if a change in control of the Company is consummated prior to January 31, 2026.
18
Table of Contents